Michael Siluk | UCG | Universal Images Group | Getty Images<\/p>\n
Novo Nordisk<\/a> rose as much as 4% after England’s drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes. <\/p>\n Wegovy is mainly a weight loss treatment but it is also approved for reducing the risk of major cardiovascular events in people living with overweight or obesity. <\/p>\n The new recommendation the National Institute for Health and Care Excellence (NICE), England’s drug price regulator, will significantly expand access to Wegovy on the country’s National Health Service (NHS). <\/p>\n The regulator, which assesses a medicine’s cost-effectiveness, recommended semaglutide, the active ingredient in Wegovy and diabetes treatment Ozempic, as an option for adults who have previously had a heart attack, a stroke, or a serious circulation problem in the legs and who have a body mass index (BMI) of at least 27.<\/p>\n Novo’s Copenhagen-listed shares were last seen up 2% in morning trading, paring some earlier gains. The pan-European blue-chip index<\/a> Stoxx 600<\/a> was up 2.1%.<\/p>\n This is a breaking news story. Please refresh for updates.<\/p>\n